MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Sutro Biopharma, a Bay Area oncology biotech company, is laying off around half its staff, switching up its leadership team ...

The Dow Jones and S&P 500 posted robust gains Friday afternoon. Nvidia led the Dow and Ulta topped the S&P 500 on the stock ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

MoonLake Immunotherapeutics expects mid-year readout for Phase 3 trials of sonelokimab in hidradenitis suppurativa; CEO da ...

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...